- Leading precision medicine company GNS Healthcare announced it raised $23 million in strategic funding led by Cigna Ventures
GNS Healthcare — a leading precision medicine company — announced it raised $23 million in a strategic Series D funding led by Cigna Ventures (a wholly-owned indirect subsidiary of Cigna Corporation). Amgen Ventures, Celgene, Echo Health Ventures, Alexandria Venture Investments, and former Caesar’s CEO and Aetna Division President Gary Loveman also joined this round.
“We are thrilled to have Cigna contribute to our next phase of growth,” said GNS Healthcare CEO and co-founder Colin Hill. “As one of the largest and most forward-thinking global health services companies, Cigna is the perfect complement to our cadre of leading biopharma companies and health plan partners committed to improving patient outcomes through causal AI and the precision healthcare it enables.”
GNS is a pioneer in machine learning and its application to healthcare. And GNS’s causal AI technology transforms data streams into in silico patients that precisely match therapeutics, procedures, and care management interventions to individuals to drive personalized clinical care and medicine and improve health outcomes.
With this round of funding, it will enable Cigna and others to deliver on increasing consumer demand for personalization in new and more effective ways.
“Cigna is committed to improving the total health and well-being of our customers – and the personalized clinical care interventions that we expect GNS to facilitate will play a huge role in achieving those improvements,” added Tom Richards, Global Lead, Strategy & Business Development at Cigna. “GNS aligns with our vision and together we can super-charge our advanced analytics capabilities and provide even deeper, more predictable insights that will further enhance customer access to the highest quality treatment and care, in the preferred and appropriate place, at the right time.”
Cigna is joining other leading carriers, health plans, and GNS investors, including Cambia Health Solutions, Echo Health Ventures, Horizon Blue Cross of NJ and Heritage Provider Network along with leading biopharma companies, including Amgen Ventures, Celgene Corporation and Zambon Pharmaceuticals, and other investors Mitsui, GHO Capital, Alexandria Venture Investments, Fort Rock Capital and Gary Loveman.
